서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Publications

Detailed Information

Activation of Akt signaling in rat brain by intracerebroventricular injection of ouabain: A rat model for mania

DC Field Value Language
dc.contributor.authorYu, Hyun-Sook-
dc.contributor.authorKim, Se Hyun-
dc.contributor.authorPark, Hong Geun-
dc.contributor.authorKim, Yong Sik-
dc.contributor.authorAhn, Yong Min-
dc.date.accessioned2012-07-03T04:33:34Z-
dc.date.available2012-07-03T04:33:34Z-
dc.date.issued2010-08-16-
dc.identifier.citationPROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY; Vol.34 6; 888-894ko_KR
dc.identifier.issn0278-5846-
dc.identifier.urihttps://hdl.handle.net/10371/78212-
dc.description.abstractIntracerebroventricular (ICV) injection of ouabain, a specific Na-K ATPase inhibitor, induces behavioral changes in rats resembling the manic phenotypes of bipolar disorder. The binding of ouabain to the Na-K ATPase affects signal events in vitro including Akt, a possible molecular target of mood disorders. However, the effects of ouabain on Akt in the brain need further clarification. In this study, we investigated changes in the phosphorylation state of Akt in the rat brain after ICV injection of ouabain. Consistent with our previous report, the locomotor activity of rats within 30 min after ouabain ICV injection changed according to the dose with higher doses of ouabain, 0.5 and 1 mM, inducing significant hyperactivity. In addition, ouabain administration induced a dose-dependent increase in the immunoreactivity of p-Akt (Ser473) in the frontal cortex. striatum, and hippocampus after 30 min, and reached statistical significance with 1 mM of ouabain. Phosphorylation of GSK-3 beta (Ser9), FOX01 (Ser256), and eNOS (Ser1177), which are downstream molecules of Akt, was also increased in a dose-dependent manner within the same brain regions. Moreover, hyperactivity was seen for 8 h after a single 1 mM injection of ouabain and increased phosphorylation of Akt (Ser473), GSK-3 beta, (Ser9), FOX01 (Ser256), and eNOS (Ser1177) was also observed in the cortex, striatum, and hippocampus. Thus, intrabrain injection of ouabain induces activation of Akt signaling accompanied by hyperactivity, suggesting the possible role of Akt in ouabain rat model of mania. (C) 2010 Elsevier Inc. All rights reserved.ko_KR
dc.description.sponsorshipThis work was supported by the Korea Science and Engineering
Foundation (KOSEF) grant funded by the Korean government (MEST)
(No. R01-2008-000-11359-0).		ko_KR
dc.language.isoenko_KR
dc.publisherPERGAMON-ELSEVIER SCIENCE LTDko_KR
dc.subjectBipolar disorderko_KR
dc.subjectDigitalis-like compoundko_KR
dc.subjectNa-K ATPaseko_KR
dc.subjectGSK-3 betako_KR
dc.titleActivation of Akt signaling in rat brain by intracerebroventricular injection of ouabain: A rat model for maniako_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor유현숙-
dc.contributor.AlternativeAuthor김세현-
dc.contributor.AlternativeAuthor박홍근-
dc.contributor.AlternativeAuthor김용식-
dc.contributor.AlternativeAuthor안용민-
dc.identifier.doi10.1016/j.pnpbp.2010.04.010-
dc.citation.journaltitlePROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY-
dc.description.citedreferenceJornada LK, 2010, J PSYCHIATR RES, V44, P506, DOI 10.1016/j.jpsychires.2009.11.002-
dc.description.citedreferenceFreitas TP, 2010, J NEURAL TRANSM, V117, P149, DOI 10.1007/s00702-009-0337-3-
dc.description.citedreferenceCousins DA, 2009, BIPOLAR DISORD, V11, P787-
dc.description.citedreferenceRiegel RE, 2009, NEUROCHEM INT, V55, P491, DOI 10.1016/j.neuint.2009.05.003-
dc.description.citedreferenceHamid H, 2009, PROG NEURO-PSYCHOPH, V33, P1103, DOI 10.1016/j.pnpbp.2009.06.002-
dc.description.citedreferenceSchleicher M, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000343-
dc.description.citedreferenceAubry JM, 2009, PSYCHOPHARMACOLOGY, V205, P419, DOI 10.1007/s00213-009-1551-2-
dc.description.citedreferencePietilainen OPH, 2009, AM J MED GENET B, V150B, P683, DOI 10.1002/ajmg.b.30890-
dc.description.citedreferenceTian J, 2009, J BIOL CHEM, V284, P14921, DOI 10.1074/jbc.M808355200-
dc.description.citedreferenceWada A, 2009, J PHARMACOL SCI, V110, P14, DOI 10.1254/jphs.09R02CR-
dc.description.citedreferencePolter A, 2009, BIOL PSYCHIAT, V65, P150, DOI 10.1016/j.biopsych.2008.08.005-
dc.description.citedreferenceKrishnan V, 2008, BIOL PSYCHIAT, V64, P691, DOI 10.1016/j.biopsych.2008.06.003-
dc.description.citedreferenceBeaulieu JM, 2008, MOL INTERV, V8, P230, DOI 10.1124/mi.8.5.8-
dc.description.citedreferenceKim SH, 2008, PROG NEURO-PSYCHOPH, V32, P1637, DOI 10.1016/j.pnpbp.2008.05.027-
dc.description.citedreferencePerrine SA, 2008, J NEUROCHEM, V107, P570, DOI 10.1111/j.1471-4159.2008.05632.x-
dc.description.citedreferenceMcGinty JF, 2008, J NEUROCHEM, V104, P1440, DOI 10.1111/j.1471-4159.2008.05240.x-
dc.description.citedreferenceThiselton DL, 2008, BIOL PSYCHIAT, V63, P449, DOI 10.1016/j.biopsych.2007.06.005-
dc.description.citedreferenceLiu LJ, 2007, AM J PHYSIOL-CELL PH, V293, pC1489, DOI 10.1152/ajpcell.00158.2007-
dc.description.citedreferenceKhundmiri SJ, 2007, AM J PHYSIOL-CELL PH, V293, pC1171, DOI 10.1152/ajpcell.00535.2006-
dc.description.citedreferenceKulikov A, 2007, BBA-BIOMEMBRANES, V1768, P1691, DOI 10.1016/j.bbamem.2007.04.012-
dc.description.citedreferenceRoh MS, 2007, EXP MOL MED, V39, P353-
dc.description.citedreferenceManning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009-
dc.description.citedreferenceSeo MS, 2007, INT J NEUROPSYCHOPH, V10, P359, DOI 10.1017/S1461145706006869-
dc.description.citedreferenceNesher M, 2007, LIFE SCI, V80, P2093, DOI 10.1016/j.lfs.2007.03.013-
dc.description.citedreferenceWei Y, 2007, MOL PHARMACOL, V71, P835, DOI 10.1124/mol.106.026351-
dc.description.citedreferenceBeaulieu JM, 2007, J NEUROSCI, V27, P881, DOI 10.1523/JNEUROSCI.5074-06.2007-
dc.description.citedreferenceAperia A, 2007, J INTERN MED, V261, P44, DOI 10.1111/j.1365-2796.2006.01745.x-
dc.description.citedreferenceWilliams Jason M, 2007, PLoS Biol, V5, pe274, DOI 10.1371/journal.pbio.0050274-
dc.description.citedreferenceHerman L, 2007, NEUROSCI BIOBEHAV R, V31, P874, DOI 10.1016/j.neubiorev.2007.04.001-
dc.description.citedreferenceSCHONER W, 2007, AM J PHYSIOL-CELL PH, V293, P509-
dc.description.citedreferenceKhundmiri SJ, 2006, AM J PHYSIOL-CELL PH, V291, pC1247, DOI 10.1152/ajpcell.00593.2005-
dc.description.citedreferenceEva A, 2006, BBA-BIOMEMBRANES, V1758, P1809, DOI 10.1016/j.bbamem.2006.09.006-
dc.description.citedreferenceEl-Mallakh RS, 2006, PROG NEURO-PSYCHOPH, V30, P1261, DOI 10.1016/j.pnpbp.2006.04.003-
dc.description.citedreferenceGoldstein I, 2006, BIOL PSYCHIAT, V60, P491, DOI 10.1016/j.biopsych.2005.12.021-
dc.description.citedreferenceReif A, 2006, INT J NEUROPSYCHOPH, V9, P13, DOI 10.1017/S1461145705005560-
dc.description.citedreferenceTian J, 2006, MOL BIOL CELL, V17, P317, DOI 10.1091/mbc.E05-08-0735-
dc.description.citedreferenceKotova O, 2006, CELL MOL BIOL, V52, P48, DOI 10.1170/T760-
dc.description.citedreferenceFayard E, 2005, J CELL SCI, V118, P5675, DOI 10.1242/jcs.02724-
dc.description.citedreferenceAhn YM, 2005, INT J NEUROPSYCHOPH, V8, P607, DOI 10.1017/S1461145705005353-
dc.description.citedreferenceRuggero D, 2005, ONCOGENE, V24, P7426, DOI 10.1038/sj.onc.1209098-
dc.description.citedreferenceXu B, 2005, PLOS MED, V2, P999, DOI 10.1371/journal.pmed.0020263-
dc.description.citedreferenceYuan ZK, 2005, MOL BIOL CELL, V16, P4034, DOI 10.1091/mbc.E05-04-0295-
dc.description.citedreferenceVogt PK, 2005, CELL CYCLE, V4, P908, DOI 10.4161/cc.4.7.1796-
dc.description.citedreferenceParsa AT, 2004, TRENDS MOL MED, V10, P607, DOI 10.1016/j.molmed.2004.10.009-
dc.description.citedreferenceReif A, 2004, EUR J NEUROSCI, V20, P885, DOI 10.1111/j.1460-9568.2004.03559.x-
dc.description.citedreferenceSessa WC, 2004, J CELL SCI, V117, P2427, DOI 10.1242/jcs.01165-
dc.description.citedreferenceAccili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0-
dc.description.citedreferenceYanik M, 2004, EUR ARCH PSY CLIN N, V254, P43, DOI 10.1007/s00406-004-0453-x-
dc.description.citedreferenceKang UG, 2004, PROG NEURO-PSYCHOPH, V28, P41, DOI 10.1016/S0278-5846(03)00173-8-
dc.description.citedreferenceEl-Mallakh RS, 2003, BIPOLAR DISORD, V5, P362, DOI 10.1034/j.1399-5618.2003.00053.x-
dc.description.citedreferenceGilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026-
dc.description.citedreferenceToyota T, 2003, NEUROSCI LETT, V339, P5, DOI 10.1016/S0304-3940(02)01428-3-
dc.description.citedreferenceXie Zijian, 2003, Mol Interv, V3, P157, DOI 10.1124/mi.3.3.157-
dc.description.citedreferenceModur V, 2002, J BIOL CHEM, V277, P47928, DOI 10.1074/jbc.M207509200-
dc.description.citedreferenceDe Sarno P, 2002, NEUROPHARMACOLOGY, V43, P1158, DOI 10.1016/S0028-3908(02)00215-0-
dc.description.citedreferenceSutton G, 2002, J NEUROCHEM, V82, P1097, DOI 10.1046/j.1471-4159.2002.01031.x-
dc.description.citedreferenceGrimes CA, 2001, J NEUROCHEM, V78, P1219, DOI 10.1046/j.1471-4159.2001.00495.x-
dc.description.citedreferenceZhou XM, 2001, BIOCHEM BIOPH RES CO, V285, P46, DOI 10.1006/bbrc.2001.5126-
dc.description.citedreferenceSnyder SH, 2000, AM J PSYCHIAT, V157, P1738, DOI 10.1176/appi.ajp.157.11.1738-
dc.description.citedreferenceHaas M, 2000, J BIOL CHEM, V275, P27832-
dc.description.citedreferenceTraub Noam, 2000, Journal of Basic and Clinical Physiology and Pharmacology, V11, P375-
dc.description.citedreferencedel Peso L, 1999, ONCOGENE, V18, P7328, DOI 10.1038/sj.onc.1203159-
dc.description.citedreferenceTakaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836-
dc.description.citedreferenceGrider G, 1999, J AFFECT DISORDERS, V54, P261, DOI 10.1016/S0165-0327(98)00208-0-
dc.description.citedreferenceChalecka-Franaszek E, 1999, P NATL ACAD SCI USA, V96, P8745, DOI 10.1073/pnas.96.15.8745-
dc.description.citedreferenceRena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179-
dc.description.citedreferenceTang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741-
dc.description.citedreferenceBrunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4-
dc.description.citedreferenceRose AM, 1998, BIOL PSYCHIAT, V44, P892, DOI 10.1016/S0006-3223(97)00440-X-
dc.description.citedreferenceRuktanonchai DJ, 1998, PHYSIOL BEHAV, V63, P403, DOI 10.1016/S0031-9384(97)00457-5-
dc.description.citedreferencePaxinos G, 1998, RAT BRAIN STEREOTACT-
dc.description.citedreferenceEmamghoreishi M, 1997, AM J PSYCHIAT, V154, P976-
dc.description.citedreferenceLi R, 1997, MOL CHEM NEUROPATHOL, V31, P65, DOI 10.1007/BF02815161-
dc.description.citedreferenceLooney S W, 1997, Depress Anxiety, V5, P53, DOI 10.1002/(SICI)1520-6394(1997)5:2<53::AID-DA1>3.0.CO-
dc.description.citedreference2-6-
dc.description.citedreferenceELMALLAKH RS, 1995, PROG NEURO-PSYCHOPH, V19, P955, DOI 10.1016/0278-5846(95)00123-D-
dc.description.citedreferenceBREDT DS, 1994, NEURON, V13, P301, DOI 10.1016/0896-6273(94)90348-4-
dc.description.citedreferenceROSKAMS AJ, 1994, NEURON, V13, P289-
dc.description.citedreferenceCHRISTO PJ, 1993, MED HYPOTHESES, V41, P378, DOI 10.1016/0306-9877(93)90089-9-
dc.description.citedreferenceDUBOVSKY SL, 1992, AM J PSYCHIAT, V149, P118-
dc.description.citedreferenceDUBOVSKY SL, 1991, BIOL PSYCHIAT, V29, P441, DOI 10.1016/0006-3223(91)90266-O-
dc.description.citedreferenceDUBOVSKY SL, 1989, ARCH GEN PSYCHIAT, V46, P632-
dc.description.citedreferenceNAYLOR GJ, 1971, BRIT J PSYCHIAT, V118, P219, DOI 10.1192/bjp.118.543.219-
dc.description.citedreferenceNAYLOR GJ, 1970, J PSYCHOSOM RES, V14, P173, DOI 10.1016/0022-3999(70)90027-9-
dc.description.tc5-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

Show Simple Item Record
Find it @ SNU

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share

qrcode
SNS Share